These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29173600)

  • 1. A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications.
    Brouillette J; Nattel S
    Can J Cardiol; 2017 Dec; 33(12):1577-1586. PubMed ID: 29173600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale.
    Manolis TA; Manolis AA; Manolis AS
    Angiology; 2019 Feb; 70(2):103-129. PubMed ID: 29874922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are psychotropic drugs at therapeutic levels a concern for cardiologists?
    Burggraf GW
    Can J Cardiol; 1997 Jan; 13(1):75-80. PubMed ID: 9039069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 2: Strategies to Minimize Adverse Outcomes From Unintended DDIs.
    Preskorn SH
    J Psychiatr Pract; 2018 Sep; 24(5):341-347. PubMed ID: 30427821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac side effects of psychiatric drugs.
    Mackin P
    Hum Psychopharmacol; 2008 Jan; 23 Suppl 1():3-14. PubMed ID: 18098218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Psychiatric patients and QT interval monitoring].
    Girardin F; Gaspoz JM
    Rev Med Suisse; 2007 Apr; 3(106):945-8. PubMed ID: 17575970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Side effects of psychotropic medication: Suggestions for clinical practice].
    Grunze A; Mago R; Grunze H
    Dtsch Med Wochenschr; 2017 Nov; 142(22):1690-1700. PubMed ID: 29078215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular side effects of psychopharmacologic therapy.
    Potočnjak I; Degoricija V; Vukičević Baudoin D; Čulig J; Jakovljević M
    Int J Cardiol; 2016 Sep; 219():367-72. PubMed ID: 27352209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avoiding psychotropic drug interactions in the cardiovascular patient.
    DeVane CL; Markowitz JS
    Bull Menninger Clin; 2000; 64(1):49-59. PubMed ID: 10695159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiovascular monitoring of psychotropic drugs].
    Momomura S
    Seishin Shinkeigaku Zasshi; 2014; 116(2):123-9. PubMed ID: 24712272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management.
    Fanoe S; Kristensen D; Fink-Jensen A; Jensen HK; Toft E; Nielsen J; Videbech P; Pehrson S; Bundgaard H
    Eur Heart J; 2014 May; 35(20):1306-15. PubMed ID: 24644307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs.
    Gutgesell H; Atkins D; Barst R; Buck M; Franklin W; Humes R; Ringel R; Shaddy R; Taubert KA
    J Am Acad Child Adolesc Psychiatry; 1999 Aug; 38(8):1047-50. PubMed ID: 10434498
    [No Abstract]   [Full Text] [Related]  

  • 15. [Psychopharmacotherapy in patients with cardiovascular diseases].
    Cordes J; Lange-Asschenfeldt C; Hiemke C; Kahl KG
    Internist (Berl); 2012 Nov; 53(11):1304, 1306-12, 1314. PubMed ID: 23052329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acting out and psychoactive substances: alcohol, drugs, illicit substances].
    Gillet C; Polard E; Mauduit N; Allain H
    Encephale; 2001; 27(4):351-9. PubMed ID: 11686057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical cardiac safety assessment of drugs.
    Hanton G
    Drugs R D; 2007; 8(4):213-28. PubMed ID: 17596108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical management of cardiovascular risks during treatment with psychotropic drugs.
    Glassman AH
    J Clin Psychiatry; 2002; 63 Suppl 9():12-7. PubMed ID: 12088171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of psychotropic drugs.
    Kovacs D; Arora R
    Am J Ther; 2008; 15(5):474-83. PubMed ID: 18806524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.